Recent Oral Therapy Developments in Psoriasis, With April W. Armstrong, MD, MPH

 therapies has expanded in recent years, and new data has emerged in recent dermatology meetings expanding upon these drugs’ use among those with inflammatory diseases.

American Academy of Dermatology (AAD) Annual Meeting

 in Denvrer, April W. Armstrong, MD, MPH, of UCLA, spoke about several key highlights from her session on psoriasis, emphasizing the rapidly expanding role of oral medications for individuals with moderate-to-severe plaque psoriasis.

“In this particular session, I refer to both the FDA-approved advanced oral therapies that we've been using for a while, things such as deucravacitinib, as well as apremilast annd our newly FDA-approved oral therapy, icotrokinra,” Armstrong explained.

Armstrong touched on an array of emerging agents known to be reshaping clinical decision-making in the field, including established oral options such as deucravacitinib and apremilast. She also noted icotrokinra’s recent findings regarding its efficacy, pointing to its comparable efficacy to biologics. She noted that these advancements signal a shift toward oral agents as a “next frontier,” providing patients effective, convenient alternative options with favorable safety profiles.

One key aim of her AAD session was to explore the increasing role of TYK2 inhibition. During her discussion of the session, she highlighted the recent milestone of deucravacitinib’s US Food and Drug Administration (FDA) approval for psoriatic arthritis, in addition to its established role in psoriasis. The data, she noted, underscore its growing utility across disease manifestations.

Armstrong further pointed to next-generation TYK2 inhibitors currently in development, which may offer increased specificity and potency, with early results indicating improved clinical performance. Beyond therapeutics, she noted broader themes discussed during the talk, including the value of early intervention, particularly in psoriatic arthritis, to potentially alter long-term disease trajectories for patients.

Additionally, she discussed the ongoing debate the dermatologist’s role in managing comorbidities such as obesity in collaboration with other specialties. Later, she highlighted encouraging data in pediatric and adolescent populations, noting that many medications with FDA approvals for adults appear to be equally, if not more, effective in younger individuals. Taken together, Armstrong framed the current moment in psoriasis care as one of significant progress, marked by expanding options.

The quotes in this video summary were edited for clarity.

Armstrong served as a consultant for and received honoraria from AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, and UCB and has participated in advisory boards for Boehringer Ingelheim and Parexel.

Armstrong A, et al. S043 Psoriasis. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Johnson and Johnson. FDA approves ICOTYDE (icotrokinra), the first and only targeted oral peptide IL-23 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis. Press release. Published March 18, 2026. Accessed April 21, 2026. 

https://www.jnj.com/media-center/press-releases

Videos

Armstrong’s interview highlights oral therapies in the psoriasis treatment space highlighted in her session at the 2026 AAD meeting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

First-Generation Gene Editing in Sickle Cell Faces Real-World Limits Despite Breakthrough Results

Reni-cel Builds on Promising Early Clinical Gains

Emerging data on renizgamglogene autogedtemcel (reni-cel) continue to position gene editing as a potential “functional cure” for 

, with early-phase findings demonstrating sustained increases in fetal hemoglobin and marked reductions in vaso-occlusive events.

As previously reported, the investigational therapy uses a CRISPR gene editing–Cas12a approach to modify autologous hematopoietic stem cells, enabling increased fetal hemoglobin production and prevention of red blood cell sickling.

However, experts caution that current approaches represent an early iteration of gene-based therapies.

 of our conversation with Rabi Hanna, MD, the lead author and chair of the Pediatric Hematology – Oncology & Blood and Bone Marrow Transplant Division at Cleveland Clinic Children’s, for insights into pain crisis reductions and its mechanism as a “functional cure”.

“First-Generation” Therapy Still Faces Safety and Delivery Challenges

, Rabi Hanna emphasized that, despite strong clinical outcomes, significant limitations remain in how these therapies are delivered.

“This is really very exciting in terms of seeing a result of gene therapy, but I would call this first-generation gene therapy. We need advances in conditioning—right now we are using myeloablative busulfan, which is very strong and can cause long-term side effects, including infertility. It is on us to find better ways to deliver this without those unnecessary risks,” Hanna said.

A key barrier is the continued reliance on myeloablative conditioning, as well as inefficiencies in stem cell collection and manufacturing. Patients with sickle cell disease often require multiple collection cycles due to disease-related bone marrow challenges, and current gene-editing processes require large numbers of stem cells, increasing time and resource burden.

Access, Cost, and Development Hurdles Limit Broader Adoption

Despite its promise, gene therapy remains limited by cost and infrastructure requirements, restricting availability to specialized centers.

Broader structural challenges are also emerging. A program sponsored by Editas Medicine was discontinued despite encouraging results, reflecting the financial and logistical barriers associated with late-stage development.

These challenges underscore the need for more flexible regulatory pathways and new payment models, particularly for rare and resource-intensive therapies, to ensure broader and more equitable access.

“Functional Cure” Translates to Real-World Patient Freedom

Although gene editing does not eliminate all aspects of disease biology, its ability to restore red blood cell function has led clinicians to describe it as a functional cure.

“I use the word functional cure quite a lot, because I want to make sure patients understand we are curing the red blood cells, not the rest of the body—but what we are seeing is that this is really giving them freedom to pursue their dreams. I have patients now going to nursing school, others doing things like skydiving that they could never have imagined before,” Hanna said.

Editor’s Note: Hanna reports relevant disclosures with Chiesi USA, Inc., Swedish Orphan Biovitrum AB (Sobi), and Vertex Pharmaceuticals Incorporated.

Hanna R, Frangoul H, Pineiro L, et al. CRISPR-Cas12a Gene Editing of 

 Promoters to Treat Sickle Cell Disease. 

Hanna R. One-Time Gene-Editing Therapy Gives Patients “Freedom” From Pain Crisis. HCPLive. Published April 17, 2026. Accessed April 21, 2026. 

https://www.hcplive.com/view/one-time-gene-editing-therapy-gives-patients-freedom-from-pain-crisis

Hanna R. Can Gene Editing Be A “Functional Cure” For Sickle Cell Disease?. HCPLive. Published April 16, 2026. Accessed April 21, 2026. 

https://www.hcplive.com/view/can-gene-editing-be-a-functional-cure-for-sickle-cell-disease

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Hematology

Strategic Alliance Partnership

Anick Bérard PhD, a researcher at CHU Sainte-Justine in Montreal, professor at the University of Montreal, and an adjunct professor Université Claude Bernard Lyon 1.

Asthma Controllers Safe in First Trimester, With Anick Bérard, PhD

 controller medications was not associated with an increased risk of major congenital malformations, according to new population-based cohort data discussed by Anick Bérard, PhD, from CHU Sainte-Justine.

“This is reassuring for those who actually prescribe to pregnant women with asthma some medications,” Bérard said. “It’s also reassuring for the mom who wonders whether she needs to stop her medications or continue.”

In their population-based cohort study, Bérard and colleagues sought to assess the association between first-trimester use of 5 common asthma controller regimens and the risk of major congenital malformations in the offspring of women with asthma. Investigators included 44,435 singleton live births to mothers with asthma from the 2003 to 2021 AM-PREGNANT cohort (American Pregnancy-Mother-Child Cohort) and compared outcomes across 5 controller regimens: montelukast, inhaled corticosteroids (ICS), montelukast plus ICS combination, ICS plus long-acting beta agonists (LABA), and montelukast plus ICS plus LABA combination. Medication exposure was based on first-semester prescription fills.

Across groups, first-trimester exposure to these medications was not linked to an increased risk of major congenital malformations compared with no controller medication use. Bérard noted the results align with longstanding Global Initiative for Asthma (GINA) guideline recommendations but add strength through a substantially larger cohort.

The analysis also addressed concerns surrounding montelukast use following a 2020 boxed warning related to neuropsychiatric events in adolescents. Bérard said the warning contributed to reduced prescribing during pregnancy despite limited pregnancy-specific safety data. By including nearly 3000 pregnant individuals exposed to montelukast, the study provided one of the largest evaluations of this medication in pregnancy to date. The absence of an increased malformation risk in this larger sample helps clarify prior uncertainty from smaller studies.

Investigators additionally compared monotherapy and combination regimens. Bérard reported no meaningful differences across various regimens. These findings support the relative safety of maintaining controller therapy when clinically indicated.

A potential signal emerged for cleft palate or cleft lip among individuals receiving montelukast plus ICS, although event numbers were < 5. Bérard emphasized caution in interpreting this observation, noting the rarity of the outcome.

“You have to remember that the baseline prevalence of cleft lip, cleft palate in the general pregnant population is quite low, less than 1%, so even if we've seen a very small increase in risk, it remains very rare,” Bérard said. “You always balance the risk with the benefit of using the medication, and in our study, we didn't look at benefits at all. We just looked at [the] risk of malformation. Just keep in mind [this study] needs to be replicated [with a] larger sample size.”

Jiao XF, Leal LF, Ducharme FM, Tse SM, Bérard A. First-trimester asthma controller medication use and major congenital malformation risk in offspring of women with asthma: A nationwide population-based cohort study. 

In an interview, Bérard discusses population-based data showing no increased risk of major congenital malformations with first-trimester asthma controller use.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Aliza Narva, JD, BSN, MSN, director of ethics at the Hospital of the University of Pennsylvania.

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

In this Q&A, Dominic Sisti, PhD, from Penn Medicine, speaks with Aliza Narva, JD, MSN, the director of ethics at the Hospital of the University of Pennsylvania, about her path from law and nursing to clinical ethics consultation and how ethics services function in practice at Penn Medicine.

Narva discusses the interdisciplinary process behind ethics consults, including chart review, engagement with care teams, and conversations with patients and families. She also outlines common sources of ethical conflict, particularly end-of-life decision-making and clinician moral distress, and reflects on a complex, prolonged ICU case that shaped her perspective on balancing policy, compassion, and family dynamics.

This Q&A is a snippet from our latest episode of Medical Ethics Unpacked, all about clinical ethics consultations. Watch the episode here: 

Medical Ethics Unpacked: Clinical Ethics Consultation in Practice

Sisti: Why did you gravitate towards ethics consultation after receiving your JD from Pennsylvania Law School and your bachelor’s and master’s degrees in nursing from Penn?

It started with having a humanities undergraduate degree. Before I went to law school, I was an American studies major at Occidental College in Los Angeles, and I really was focused on and interested in civil rights. I had this idea in undergrad that I would go to law school, and I would end up studying constitutional law and practicing, and that is not what happened to me. Like so many people who go to law school, I ended up coming out with massive debt and sort of got funneled into a large corporate firm where I felt really bored but also anxious, which was a particularly bad combination for me. After a couple of years of practicing corporate law, it became clear to me that I was going to need to do a different thing.

I started to go back to parts of my undergrad education that I had really loved, and then I had worked for 2 years after college in a women's health clinic, and I had really loved that healthcare environment. It was largely run by nurses and nurse practitioners and was really focused on the individual needs of patients, who were folks who often felt very marginalized.

I decided I was going to go back to school. I thought I would go straight through and become a nurse practitioner. Like so many people, I really didn't have a clear idea of what clinical nurses do. I sort of thought of them in this sort of stereotypical way of little lady helpers with little paper hats, and I was obviously quite wrong.

During nursing school, I really fell in love with clinical nursing and being in a hospital, just how dynamic it is. You have this group of people who are all focused on doing the right thing for patients; it really was that same theme of thinking about individual rights, making sure that people are not getting marginalized.

During orientation, [I] met our clinical ethicist, and was like, Yep, that's it. That's the thing I really do. She mentored me. I was able to have her shadow me for years, read my notes, and educate me. I got additional ethics training…and learned the mediation approach to ethics consultation, which is the model that we use here, and it all felt very consistent with that initial inspiration, even in college, of really trying to think about, how are we making sure that individuals who may not have access to the things they need have the best chance of getting what they need.

Sisti: What do you do when you get an ethics consultation request? Do you have a standard process, and what's the result?

A lot of what we do in our model is very traditional in terms of ethics consultation. We typically have one person who's covering the service we offer consultation, 24/7, just with the caveat of like, if it's not an emergency, consider not calling at 3 in the morning. There's always someone who is going to call you back if you have a question.

Whoever's covering will spend a little bit of time talking to the person, [asking] what's going on? What do you think is the ethical issue?

What we will typically do is spend some time in the patient's chart. What is this person's history? Why are they here? What has their experience been? Who are the key players in their health journey?

We really like to make sure we're talking to the clinical team, so not just the person who called, but also the other members. If the resident called, I want to talk to the attending. I want to talk to the nurse. I want to talk to [a] social [worker]. Maybe respiratory therapy is really involved. I'm going to want to talk to that person. And then, really, the standard of practice is also to talk to patients and families.

Sisti: If you had to summarize your top 3 kinds of issues, what are the general ethical conflicts that you see that often come up?

We have a ton of stuff that comes up at [the] end of life. The patient may no longer be able to advocate for themselves, and there's disagreement about what the next step should be in treatment. Are we going to withhold life-sustaining therapies? Are we going to escalate care for this person to the ICU? Is dialysis appropriate?

Another thing that comes up a lot is moral distress. Clinicians…often [feel] morally constrained from doing the thing that they think is the right thing to do or… uncertain about what the right thing is to do. That is definitely a completely appropriate time to call an ethics consult because the ethics consultant is there to help you think through, what are my ethical obligations? Who is the surrogate decision maker?

Sisti: Is there a particular case that stands out from your career that's been either haunting you or you feel proud of?

There was a case a couple of years ago, now maybe 7 years ago. Nothing about this is especially unique, except for her length of stay. There was a woman who suffered from an arrest [and] was in a persistent vegetative. She was in the neuro ICU for a year and a half, and I was new in this role and… thinking about a lot of the literature out [at] the time. [I] was thinking about policies related to how…you respond to potentially inappropriate requests for care from families. What do we do when families are asking for things that just aren't medically indicated? It may not be that they're actually physiologically futile, but they probably aren't going to do the thing that families want them to do. I think I was less generous then. I was very into this policy.

This patient…was 65 years old. She had two adult sons, she had a husband, she was really a matriarch in her community. She had another very rare disease, a neurological disease that had taken like 15 years to diagnose, which predated this terrible arrest. And so, this husband had this traumatic experience, and he really wanted to keep going.

There were meetings and meetings and meetings…with him, and he felt like even just having her heart beating would be all that she would want. It was tricky because I really saw the impact on the patient and her body. She was in the ICU for a long time, so her body just started to really fall apart. I saw the impact on the team and on the staff and how distressed folks felt, continuing to provide these aggressive treatments, keeping her intubated, giving her feeds through the pig tube. She was on dialysis at times. It was a lot.

I wasn't at the point where I could appreciate or understand that the history that they'd had as a family was really explaining the story of where they were now and why he didn't want to let go. Her very long time to get this diagnosis of this rare disease was really informing his goals and wishes.

Questions and answers are edited for clarity.

Articles

In a Q&A with Dominic Sisti, Narva discusses ethics consult workflows, common conflicts, and lessons from complex ICU cases.



Clinical Ethics Consultation in Practice, With Aliza Narva, JD, MSN

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Ravulizumab (Ultomiris) reduced proteinuria as early as week 10 and met its primary endpoint at week 34 in a prespecified interim analysis of the phase 3 I CAN trial, demonstrating a statistically significant and clinically meaningful reduction in proteinuria among adults with 

AstraZeneca announced positive topline results based on the change from baseline in 24-hour urine protein-creatinine ratio (UPCR) at week 34, supporting terminal C5 complement inhibition as a potential disease-modifying approach in IgAN. The trial’s second primary endpoint, change in estimated glomerular filtration rate (eGFR), will be assessed at week 106.

“Many people living with IgAN continue to progress to kidney failure, ultimately requiring dialysis or a transplant—outcomes that can place profound burden on patients’ daily lives—despite advances in care,” said Jonathan Barratt, MD, Mayer Professor of Renal Medicine at the University of Leicester, United Kingdom, and I CAN trial investigator. “The interim I CAN results demonstrate that blocking terminal complement activation, a central driver of kidney inflammation in IgAN, with Ultomiris may play a promising role in reducing proteinuria. We look forward to understanding the full clinical impact of Ultomiris in treating this disease following study completion at two years.”

Ravulizumab inhibits complement protein C5, preventing its cleavage into C5a and C5b-9—key drivers of inflammation and kidney damage. By targeting terminal complement activation, the therapy may reduce inflammation and slow the progression of kidney injury in IgAN.

The global, phase 3, randomized, double-blind, placebo-controlled I CAN (ALXN1210-IgAN-320) trial is evaluating ravulizumab in approximately 510 adults with biopsy-confirmed IgAN across 28 countries. Participants were required to be on stable background therapy consistent with standard of care for at least 3 months prior to screening and were randomized 1:1 to receive ravulizumab or placebo.

Ravulizumab was administered intravenously, beginning with a loading dose followed by weight-based maintenance dosing every 8 weeks for a total treatment duration of 106 weeks.

The primary endpoints are change from baseline in proteinuria (UPCR) at week 34 and change in eGFR at week 106, assessed at the interim and final analyses, respectively. Key secondary endpoints include ≥50% reduction in UPCR at week 34, change in UPCR at week 10, time to sustained ≥30% decline in eGFR, and time to first composite kidney event through week 106.

The safety profile observed in the trial was consistent with the known profile of ravulizumab, with no new safety concerns identified.

AstraZeneca indicated it plans to seek accelerated approval in key markets and will present full data from the trial at an upcoming medical meeting.

Phase 2 data previously presented at Kidney Week 2023

 showed greater proteinuria reduction with ravulizumab (40.3%) compared with placebo (10.9%) at 26 weeks, with a treatment effect of 33.1% (90% CI, 14.7-47.5; P = .0012). 

 in patients aged ≥1 month, as well as several other complement-mediated conditions.

Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial. Astrazeneca.com. Published April 21, 2026. Accessed April 21, 2026. 

https://www.astrazeneca.com/media-centre/press-releases/2026/i-can-phiii-interim-analysis-met-primary-endpoint.html

Valentine A. I CAN - ALXN1210-IgAN-320 Study. Igan.org. Published September 4, 2024. Accessed April 21, 2026. 

https://igan.org/clinical-trial/alxn1210-igan-320-study

Ravulizumab achieved a statistically significant, clinically meaningful reduction in proteinuria in adults with biopsy-confirmed IgA nephropathy, with effects evident by week 10 and meeting the interim primary endpoint at week 34 (24-hour UPCR change). Findings support terminal complement inhibition via C5 blockade as a potential disease-modifying strategy. The ongoing global phase 3, double-blind I CAN trial will evaluate the second primary endpoint, eGFR change, at week 106, alongside kidney-outcome time-to-event secondary endpoints. No new safety signals emerged.

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Breaking News

Ravulizumab Reduces Proteinuria as Early as Week 10 in Phase 3 I CAN Trial for IgAN

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

When First-Line Fails: The Rising Threat of Treatment-Resistant Dermatoses

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

If approved, the novel corticosteroid therapy would be the first and only FDA-approved hydrocortisone acetate suppository.

FDA News

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

FDA Accepts NDA For Next-Generation Hydrocortisone Acetate in Ulcerative Colitis of the Rectum

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

The FDA accepted Genentech's sBLA for obinutuzumab in SLE based on positive phase 3 ALLEGORY trial results, with a decision expected by December 2026.

FDA Accepts sBLA for Obinutuzumab (Gazyva) in Systemic Lupus Erythematosus

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.


Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Shifting Treatment Goals and Povorcitinib's Benefit in HS, With Martina Porter, MD

Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

White House Order Accelerates Psychedelic Research for Mental Illness, With Gus Alva, MD

Phillip Levy is an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine.

Chronic Kidney Disease

Mobile Health Units Aim to Close Gaps in CKD Screening Access

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Experts call for greater awareness, improved collaboration with OB/GYNs, and more proactive MASLD screening strategies for women.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Screening Smarter: Identifying MASLD Risk in Women

Ashkan Shoamanesh, MD, is an associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University.

Shoamanesh discusses the positive data from OCEANIC-STROKE, a phase 3 trial comparing the investigative FXIa inhibitor to placebo in patients with prior ischemic stroke.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Asundexian Reduces Stroke Incidence Without Increasing Bleeding, With Ashkan Shoamanesh, MD

Marie-José van Tol, PhD, from the University of Groningen.

Preventive cognitive therapy may reduce relapse in recurrent depression by strengthening positive affect and addressing anhedonia, van Tol explained.


Targeting Positive Affect May Prevent Depression Relapse, With Marie-José van Tol, PhD

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

Latest News

Recent Oral Therapy Developments in Psoriasis, With April W. Armstrong, MD, MPH

First-Generation Gene Editing in Sickle Cell Faces Real-World Limits Despite Breakthrough Results

Asthma Controllers Safe in First Trimester, With Anick Bérard, PhD

Clinical Ethics Consultation in Practice, With Aliza Narva, JD, MSN

Ravulizumab Reduces Proteinuria as Early as Week 10 in Phase 3 I CAN Trial for IgAN